Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
Roche has entered a $2.5 billion licensing agreement with Hanmi Pharm to secure rights to a novel clinical-stage obesity therapy.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 5.
Source diversity sample: SWI swissinfo.ch · BioSpace · Endpoints News · FirstWord Pharma · Investing.com · PR Newswire · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
The reporting (7)
- Roche snags rights to South Korean obesity treatment SWI swissinfo.ch · 16h ago
- Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug BioSpace · 16h ago
- Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset Endpoints News · 16h ago
- Roche makes $2.3B bet on Hanmi’s muscle-sparing obesity asset FirstWord Pharma · 16h ago
- Hanmi Pharm shares jump 30% on Genentech obesity drug deal Investing.com · 16h ago
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy PR Newswire · 16h ago
- Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism Fierce Biotech · 16h ago
The story so far
This partnership grants Genentech, a member of the Roche Group, exclusive rights to a therapeutic candidate designed to address obesity through a mechanism focused on muscle preservation. The deal involves a commitment of up to $2.5 billion, with specific reports from Endpoints News and FirstWord Pharma detailing a $2.3 billion figure tied to the asset.
The financial markets responded immediately to the announcement, as Hanmi Pharm shares increased by 30% following the news of the collaboration with Genentech. While the agreement is confirmed, the specific timeline for future clinical development and regulatory filings is not yet specified.
Coverage does not yet clarify the exact mechanism of action for the drug or the anticipated date for upcoming trial data releases.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 7h ago.
The obvious questions
What is the financial value of the deal?
Reports vary between $2.3 billion and $2.5 billion.
Who is involved in the partnership?
Hanmi Pharm has signed an exclusive licensing deal with Genentech, which is part of Roche.
What is the focus of the drug?
The drug is a clinical-stage obesity therapy specifically targeting muscle-sparing or muscle-building mechanisms.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance for the first blood-based biomarker test for Alzheimer's disease, developed through a partnership between Roche and Eli Lilly.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
A cancer vaccine breakthrough has investors rethinking Moderna's future.
Promising new weight loss and diabetes treatment helps burn fat while keeping muscle in preclinical study
A new treatment could revolutionize weight loss and diabetes management by targeting fat while preserving muscle.
Could GLP-1s help with alcohol use disorder? A Philly VA doctor is leading a national trial to find out.
A national trial is exploring whether GLP-1s, known for weight loss, can also help with alcohol use disorder.
A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
A drug designed to mimic exercise has passed its first human test, sparking interest in the medical community.
A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High
Amylyx Pharmaceuticals' stock surges after a GLP-1 antagonist drug shows promise in a new application.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.